Lubiprostone

Evidence Level: L5 Predicted Indications: 10

Table of Contents

  1. Lubiprostone
    1. Pharmacist Assessment Report
    2. Lubiprostone: Alopecia
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. India Market Information
    7. Safety Considerations
    8. Conclusion and Next Steps
    9. Disclaimer

Pharmacist Assessment Report

Lubiprostone: Alopecia

One-Sentence Summary

Lubiprostone is a ClC-2 chloride channel activator (a prostone-class compound) used to treat chronic constipation and irritable bowel syndrome. The TxGNN model predicts it may be effective for alopecia, but no clinical trials and no publications currently support this direction. The prediction is a computational signal only.

Quick Overview

Item Content
Original Indication Not recorded in the local data
Predicted New Indication Alopecia
TxGNN Prediction Score 0.9993
Evidence Level L5
India Market Status Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products 1 (valid: 1)
Recommended Decision Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. From pharmacology data, lubiprostone is a ClC-2 chloride channel activator (target gene CLCN2) that acts on the gut epithelium. It is a bicyclic fatty acid derived from prostaglandin E1, and it has minimal systemic absorption.

No established mechanistic link between ClC-2 activation and hair follicle biology was identified. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Prostaglandin analogues such as bimatoprost do affect hair growth, but lubiprostone does not act on the same receptors. This explanation is therefore speculative and cannot be verified.

The other top predictions fall into two groups:

  • Hair disorders: congenital hypotrichosis milia (0.9993), hypotrichosis simplex of the scalp (0.9993) and diffuse alopecia areata (0.9993). These likely echo the same signal as alopecia rather than providing independent support. Alopecia areata is autoimmune, and lubiprostone has no known immunomodulatory action relevant to it.
  • Vascular and other conditions: pulmonary hypertension (0.9986), kyphoscoliotic heart disease (0.9981), Raynaud disease (0.9964), autosomal recessive primary pulmonary hypertension (0.9954), phaeochromocytoma (0.9950) and peripheral vascular disease (0.9940). The vascular links rest on the prostanoid scaffold shared with prostacyclin or alprostadil analogues. Lubiprostone has little systemic exposure and no demonstrated vasodilatory effect. No plausible mechanism was identified for phaeochromocytoma.

All ten predictions have evidence level L5 and a Hold recommendation.

India Market Information

Authorization Number Product Name Dosage Form Approved Indication
121000 Lubowel 24 Soft Gelatin Capsule (Sun Pharmaceutical Industries Ltd) Strip of 15 soft gelatin capsules (oral) Not stated in the license record

Safety Considerations

  • Drug Interactions:
    • Idelalisib: Moderate interaction (DDInter).
    • ClC-2 (CLCN2): this is the pharmacological target of lubiprostone, not an interacting drug.

Please refer to the package insert for other safety information, including warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials or publications, and no plausible mechanism links a gut-acting ClC-2 activator with minimal systemic absorption to hair loss. The package insert safety data are also missing.

To proceed, the following is needed:

  • Obtain the package insert (warnings and contraindications) from the India Pharma source
  • Obtain mechanism of action data from DrugBank
  • Perform a systematic literature and trial search on lubiprostone or prostone compounds and hair growth
  • Run preclinical studies (for example, hair follicle models) to test any biological plausibility
  • Assess route compatibility, since the only available route is oral and a topical or systemic route may be needed for hair or vascular indications

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.